As part of our ongoing commitment to prostate cancer patients, it is with great satisfaction that we present a new test for Prostate Cancer: Prolaris, an innovative test that provides important answers to doctors and patients.
Prolaris® has proven to be of clinical utility to customize the management of prostate cancer and is widely validated with:
- All risk groups
- All of the oncological assessment criteria recommended by the NCCN (BCR, Mets, DSM)
- All main therapeutic modalities, including conservative treatment